The studies indicated that the presence of mutations in almost all major cancers makes RAS proteins a significant therapeutic target, in particular for KRAS, because it was recognized as one of the most frequently mutated oncogenes [10,11,12,13,14,15]. This evidence concerns the gene KRAS and cancer.